<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37530975</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-7209</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Angiogenesis</Title><ISOAbbreviation>Angiogenesis</ISOAbbreviation></Journal><ArticleTitle>Embracing Imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19.</ArticleTitle><Pagination><StartPage>481</StartPage><EndPage>483</EndPage><MedlinePgn>481-483</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10456-023-09889-2</ELocationID><Abstract><AbstractText>Imatinib, an ABL tyrosine-kinase inhibitor, shows promise in restoring endothelial barrier function in patients with COVID-19, thus, preventing cytokine leakage from the alveolar compartment to the systemic compartment. COVID-19 is characterized by an alveolar cytokine storm, and imatinib has been shown to strengthen the endothelial barrier and mitigate alveolar inflammatory responses by modulating NF-&#x3ba;B signaling. Incorporating imatinib into COVID-19 treatment strategies offers a novel approach to safeguard the endothelial barrier and address the complex pathophysiology of the disease, including its potential implications in long COVID. Given that endothelial dysfunction plays a central role in COVID-19 progression and long COVID development, protecting the endothelial barrier during acute infection is crucial in preventing the persistent endothelial dysfunction associated with long COVID.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kow</LastName><ForeName>Chia Siang</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>School of Pharmacy, International Medical University, 126, Jalan Jalil Perkasa, Bukit Jalil, Kuala Lumpur, Malaysia. chiasiang_93@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramachandram</LastName><ForeName>Dinesh Sangarran</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasan</LastName><ForeName>Syed Shahzad</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>School of Applied Sciences, University of Huddersfield, Huddersfield, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biomedical Sciences &amp; Pharmacy, University of Newcastle, Callaghan, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Angiogenesis</MedlineTA><NlmUniqueID>9814575</NlmUniqueID><ISSNLinking>0969-6970</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8A1O1M485B</RegistryNumber><NameOfSubstance UI="D000068877">Imatinib Mesylate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001549">Benzamides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Angiogenesis. 2024 Feb;27(1):5-22. doi: 10.1007/s10456-023-09878-5</RefSource><PMID Version="1">37103631</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Angiogenesis. 2023 Nov;26(4):485-486. doi: 10.1007/s10456-023-09894-5</RefSource><PMID Version="1">37659007</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068877" MajorTopicYN="N">Imatinib Mesylate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>2</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>2</Day><Hour>11</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37530975</ArticleId><ArticleId IdType="doi">10.1007/s10456-023-09889-2</ArticleId><ArticleId IdType="pii">10.1007/s10456-023-09889-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu X, Xiang M, Jing H, Wang C, Novakovic VA, Shi J (2023) Damage to endothelial barriers and its contribution to long COVID. Angiogenesis 2023:1&#x2013;18</Citation></Reference><Reference><Citation>Kow CS, Ramachandram DS, Hasan SS (2022) The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. J Infect Chemother 28(2):257&#x2013;265</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2021.11.008</ArticleId><ArticleId IdType="pubmed">34840039</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuily S, Lef&#xe8;vre B, Sanchez O et al (2023) Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial. EClinicalMedicine 60:102031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102031</ArticleId><ArticleId IdType="pubmed">37350990</ArticleId><ArticleId IdType="pmc">10250778</ArticleId></ArticleIdList></Reference><Reference><Citation>Aman J, Duijvelaar E, Botros L, et al (2021) Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial [published correction appears in Lancet Respir Med. 2021 Aug;9(8):e84]. Lancet Respir Med 9(9):957&#x2013;968</Citation></Reference><Reference><Citation>de Brabander J, Duijvelaar E, Schippers JR et al (2022) Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients. Eur Respir J 60(6):2200780</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00780-2022</ArticleId><ArticleId IdType="pubmed">35896211</ArticleId><ArticleId IdType="pmc">9301934</ArticleId></ArticleIdList></Reference><Reference><Citation>Duijvelaar E, Gisby J, Peters J, Bogaard HJ, Aman J (2023) Longitudinal plasma proteomics reveals alveolar-capillary barrier disruption in critically ill COVID-19 patients. Res Sq 254:rs.3-rs.2872132</Citation></Reference><Reference><Citation>El-Agamy DS (2017) Nilotinib attenuates endothelial dysfunction and liver damage in high-cholesterol-fed rabbits. Hum Exp Toxicol 36(11):1131&#x2013;1145</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0960327116681649</ArticleId><ArticleId IdType="pubmed">27941169</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinveld DJB, Botros L, Maas MAW et al (2021) Bosutinib reduces endothelial permeability and organ failure in a rat polytrauma transfusion model. Br J Anaesth 126(5):958&#x2013;966</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bja.2021.01.032</ArticleId><ArticleId IdType="pubmed">33685634</ArticleId><ArticleId IdType="pmc">8258973</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>